Trial Profile

A phase III trial of CONV01-a for the treatment of patients with advanced prostate cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 10 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Apr 2024 New trial record
02 Apr 2024 According to a Convergent Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for CONV01-a, for the treatment of patients with advanced prostate cancer, which expand the scope of clinical development of CONV01-a as a monotherapy and in combination with other cancer therapies. The company will conduct Phase 2 clinical trials in 2024 preparing for a registrational program in 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com